News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Driehaus Capital Management LLC has reduced its stake in Definium Therapeutics (DFTX) to 5.36% as of June 30, 2026, down from 6.64% reported on December 31, 2025. This ownership represents 6,845,276 shares of common stock, held in various client accounts managed by DCM. The …
RBC Capital Markets highlighted that Definium Therapeutics' DT120 data from a Phase 2 proof-of-concept study, though not statistically significant, provides valuable insights into the drug's mechanisms and biomarkers. The firm believes this information significantly de-risks future trials, particularly the upcoming Phase 2b study which …
Wells Fargo & Company has raised its price target for Definium Therapeutics (NASDAQ:DFTX) to $72.00 from $68.00, maintaining an "overweight" rating and suggesting a potential upside of 68.26%. This comes amid broadly positive analyst sentiment and recent positive Phase 3 clinical trial results for …
Definium Therapeutics announced positive topline results from its Phase 3 Voyage trial for DT120 ODT in generalized anxiety disorder, meeting all primary and secondary endpoints with significant efficacy and a favorable safety profile. This milestone, achieved with its LSD-based oral dissolving tablet which holds …
RBC Capital Markets has raised its price target for Definium Therapeutics, Inc. (DFTX) to $66 from $57, while maintaining an "Outperform Speculative Risk" rating. This adjustment comes after Definium Therapeutics announced positive Phase 3 study results for its lead candidate, DT120 ODT, in treating …
Canaccord Genuity increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $64 from $58, maintaining a Buy rating, after positive Phase 3 trial results for DT120 in generalized anxiety disorder. The trial showed DT120 significantly improved Hamilton-Anxiety scores with rapid onset and good tolerability. …
Definium Therapeutics announced positive top-line results from its Phase III Voyage study for DT120 ODT in generalized anxiety disorder (GAD), meeting its primary and all key secondary endpoints with rapid and durable improvements in anxiety symptoms. The treatment, a single 100 mcg dose, showed …
Needham & Company LLC has increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $66.00 from $50.00, reiterating a "buy" rating after the company's positive Phase 3 results for its DT120 ODT anxiety treatment. Despite reporting a quarterly loss of $1.44 per share, significantly …
Definium Therapeutics announced highly positive Phase 3 results for its drug DT120 ODT (lysergide) in treating generalized anxiety disorder (GAD), demonstrating statistically significant improvement over placebo. The drug also showed rapid and sustained symptom reduction, a favorable safety profile, and is the second successful …
Definium Therapeutics announced positive topline data from its Phase 3 Voyage study, demonstrating that DT120 ODT significantly reduced HAM-A scores by 5.4 points compared to placebo at Week 12. The study met its primary and all key secondary endpoints, showing rapid onset of effect …
Definium Therapeutics (NASDAQ: DFTX) shares jumped 20% in premarket trading after announcing positive topline results from its Phase 3 Voyage study for DT120 ODT in generalized anxiety disorder. The trial met its primary and secondary endpoints, showing a statistically significant improvement in anxiety scores …
Definium Therapeutics (Nasdaq: DFTX) announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder (GAD), meeting its primary and all key secondary endpoints with high statistical significance. The study demonstrated rapid, robust, and durable efficacy, with DT120 …
Definium Therapeutics' experimental LSD-based pill, DT120, significantly reduced anxiety symptoms in a late-stage study, exceeding investor expectations. The single-dose treatment for generalized anxiety disorder (GAD) showed a statistically and clinically meaningful reduction in symptoms, with benefits appearing early and lasting throughout the 12-week study. …
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder (GAD), meeting its primary and key secondary efficacy endpoints with statistically significant reductions in HAM-A scores. The study demonstrated rapid, sustained efficacy and a favorable …
Definium Therapeutics (NASDAQ:DFTX) saw its shares drop by 6.2% to $42.34 on Tuesday, with trading volume significantly lower than average. Despite this decline and a quarterly loss exceeding analyst estimates, analysts maintain a "Buy" rating with a $55 price target. Insider selling activity has …
Shares of Definium Therapeutics (DFTX) dropped 9% as investors await crucial clinical trial data for the company's psychedelic drug, DT120, a one-time therapy for generalized anxiety disorder. This decline marks its worst day in nine months. The company, which has $1.1 billion in cash, …
H.C. Wainwright has reiterated its Buy rating for Definium Therapeutics (DFTX.US) and maintained its target price at $70. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Definium Therapeutics (DFTX) reported a wider Q2 2026 net loss of US$158.99 million but saw its stock rise 6.0% following strong Phase III DT120 ODT data for major depressive disorder and progress in generalized anxiety disorder trials. The company's investment narrative now hinges on …
This article provides a quick overview of analyst ratings for Definium Therapeutics (DFTX.US), highlighting a price target forecast ranging from $50 to $75. It emphasizes that these ratings can influence investor decisions and future stock performance for the company.
Definium Therapeutics, Inc. (NASDAQ:DFTX) has received a consensus "Buy" recommendation from eighteen analysts, with an average 12-month price target of $55.00. Despite analysts' bullish outlook and recent stock gains, the company missed its quarterly earnings estimates, reporting a loss of $1.44 per share against …
Wall Street Zen has downgraded Definium Therapeutics (NASDAQ:DFTX) to a "Sell" rating, a move that contrasts with the majority "Buy" consensus among other analysts. This downgrade follows Definium Therapeutics missing its quarterly earnings estimates significantly, reporting a loss of $1.44 per share against an …
Definium Therapeutics reported a Q2 2026 net loss of $158.986 million and a six-month net loss of $236.1 million, despite building a substantial cash reserve of $1.1 billion. This strong liquidity position, largely due to an $805 million equity offering in June 2026, is …
Definium Therapeutics, Inc. reported a significant increase in net loss for Q2 2026, reaching $(159.0)M compared to $(42.7)M in Q2 2025, with diluted loss per share rising to $(1.44). The company had no reported revenue but highlighted several clinical and regulatory advancements including fully …
Definium Therapeutics reported a wider net loss of $159 million in Q2 2026, primarily due to an $86.2 million non-cash warrant revaluation charge, even as its stock rose. The company increased R&D and G&A expenses to support late-stage trials for its lead drug DT120 …
Definium Therapeutics (DFTX) reported a Q2 EPS of -$1.44, significantly missing the FactSet estimate of -$0.54. The company's Q2 loss widened, as announced on August 6, 2026, alongside their earnings call. Definium Therapeutics focuses on developing treatments for psychiatric and neurological disorders, with its …
Definium Therapeutics (NASDAQ:DFTX) reported a Q2 net loss of $1.44 per share, significantly missing the $0.56 consensus estimate, causing shares to fall by about 4.7% after-market. The large loss was primarily due to an $86.2 million non-cash charge from warrant liabilities, although operating losses …
Definium Therapeutics reported its Q2 2026 financial results, showing a deepened net loss of $159.0 million, primarily due to an $86.2 million non-cash increase in warrant liabilities. Despite the loss, the company significantly increased its cash and investments to $1.1 billion, fueled by an …
Definium Therapeutics has granted stock options to six new non-executive employees, allowing them to purchase 115,600 common shares with a four-year vesting period. This move, made under its 2026 Inducement Plan, aims to attract talent as the company advances its late-stage psychedelic-based therapies. The …
Definium Therapeutics Inc. (DFTX) reported a wider loss in Q2 2026, posting an EPS of -$1.44, which was significantly below FactSet's estimate of -$0.54. The company, formerly Mind Medicine (MindMed) Inc., is focused on developing therapeutics for psychiatric and neurological disorders and is advancing …
Definium Therapeutics Inc is projected to report a loss of 55 cents per share, according to this earnings preview. The article, sourced from Reuters via TradingView, indicates that investors should anticipate this financial outcome for the company.
Definium Therapeutics has announced the issuance of inducement grants to six new non-executive employees. These grants consist of options to purchase a total of 115,600 common shares, effective August 3, 2026. The options will vest over a four-year period, tied to continued employment, and …
Definium Therapeutics recently reported positive topline data from its pivotal Phase 3 trial in major depressive disorder, exceeding efficacy expectations and showing durable effects. The company will host a webcast on August 6, 2026, to discuss its second-quarter 2026 financial results and business highlights. …
Search by ticker symbol or company name and select a result to open its chart.